Once-weekly REZZAYO® (rezafungin for injection) may simplify your invasive candidiasis infusion treatment

What is REZZAYO® (rezafungin for injection)?

REZZAYO® is an antifungal medication that treats invasive candidiasis, which is an infection of the bloodstream or internal organs caused by a yeast (a type of fungus) called Candida. It is given once-weekly through the vein (intravenous or IV).

REZZAYO® is approved for use in patients 18 years of age and over who have limited or no alternative options for the treatment of their infection. FDA approval of REZZAYO® was based on limited clinical safety and efficacy data. REZZAYO® was not studied in patients with Candida infections in the heart, bone, or brain.

When should I NOT take REZZAYO®?

You should not take REZZAYO® if you are allergic to rezafungin or other antifungal drugs called echinocandins.

Simplify your treatment with once-weekly REZZAYO®

There are many other echinocandin infusion treatments you may have heard of, such as caspofungin, micafungin, and anidulafungin, but REZZAYO® is different because it is dosed once-weekly.

In clinical trials with over 200 adults with candidemia and invasive candidiasis, once-weekly REZZAYO® was shown to be as effective as a daily infusion of caspofungin.

The most common side effects of REZZAYO® are fever, diarrhea, anemia, vomiting, nausea, stomach pain, constipation, and low levels of potassium, magnesium, or phosphate in the blood. Please see Important Safety Information below and full Prescribing Information.

As you can see in the chart below, with REZZAYO®, an infusion is needed only once a week—rather than daily—making it easier to fit into your schedule.

Once-weekly
REZZAYO
®
Week 1

Day 1: 400-mg loading dose

Week 2

Day 8: 200-mg weekly dose

No PICC
required*

VS

Daily IV
echinocandin

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7

Daily PICC
maintenance
to prevent
infection

*Unlike daily IV antifungal treatment, REZZAYO® does not require what is called a central IV line (often referred to as a PICC line), which is a long, thin tube that must be inserted into the arm for an extended period of time in order to administer the drug.

If you’ve been prescribed a daily antifungal infusion, such as caspofungin, micafungin, or anidulafungin, there are a few questions you may want to ask your healthcare team:

Q:

Are there other treatment options that don’t need to be taken so often?

Q:

Can I avoid
a PICC line?

Q:

Do I have to go to
an infusion center every day?

Here are a few reasons why you may want to talk to your healthcare team about once-weekly REZZAYO®:

One IV infusion once a week for 1 hour

REZZAYO® can be given at the hospital, at an infusion center, or at home by a nurse

REZZAYO® does not require a central IV line or PICC*

Copay assistance may be available for eligible patients with private commercial insurance—ask your healthcare team for information

REZZAYO® can be taken safely with other commonly prescribed medications

Once-weekly REZZAYO® is the first FDA-approved treatment of its kind in over 15 years

*Unlike daily IV antifungal treatment, REZZAYO® does not require what is called a central IV line (often referred to as a PICC line), which is a long, thin tube that must be inserted into the arm for an extended period of time in order to administer the drug.

A patient will not qualify if they have a prescription drug benefit through a government program (ie, Medicaid, Medicare, Medicare Part D, Medigap, CHAMPUS, DOD, VA, TRICARE, or any state patient or pharmaceutical assistance program).

As a condition for receiving copays or coinsurance, both healthcare professionals and patients are required to inform patients’ insurance companies and third-party payers of any copays or coinsurance benefits paid by this program.

Void where prohibited by law, taxed, or restricted. Additional terms and conditions may apply. Patients enrolled in the REZZAYO® Patient Assistance Program are not eligible. Melinta Therapeutics, LLC may determine eligibility, monitor participation, and modify or discontinue any aspect of this program at any time.

icon medical dropper

Talk to your healthcare team today about once-weekly REZZAYO® to see if it’s right for you

IMPORTANT SAFETY INFORMATION FOR PATIENTS

What is REZZAYO® (rezafungin for injection)?

REZZAYO® is an antifungal medication that treats invasive candidiasis, which is an infection of the bloodstream or internal organs caused by a yeast (a type of fungus) called Candida. It is given once-weekly through the vein (intravenous or IV).

REZZAYO® is approved for use in patients 18 years of age and over who have limited or no alternative options for the treatment of their infection. FDA approval of REZZAYO® was based on limited clinical safety and efficacy data. REZZAYO® was not studied in patients with Candida infections in the heart, bone, or brain.

What should I discuss with my healthcare provider before taking REZZAYO®?

Before starting REZZAYO®, tell your healthcare provider about all of the medications you are taking and all of your medical conditions, including if you are allergic to rezafungin or other antifungal drugs called echinocandins.

What is the most important information I need to know about taking REZZAYO®?

  • You may experience certain reactions when you are receiving REZZAYO® in the IV, including flushing, warm sensations, hives, nausea, or tightness in the chest. If these reactions occur, tell your healthcare provider. They may slow or stop the IV.
  • Photosensitivity: REZZAYO® may cause you to be more sensitive to sunlight. While taking REZZAYO®, protect yourself from sun exposure and other sources of ultra-violet (UV) radiation.
  • In the clinical trials for REZZAYO®, some patients had abnormal liver tests. Your healthcare provider will monitor you if you develop abnormal liver tests and decide whether you should keep taking REZZAYO®.

When should I NOT take REZZAYO®?

You should not take REZZAYO® if you are allergic to rezafungin or other antifungal drugs called echinocandins.

What are some of the most common side effects of REZZAYO®?

Most common side effects of REZZAYO® are fever, diarrhea, anemia, vomiting, nausea, stomach pain, constipation, and low levels of potassium, magnesium, or phosphate in the blood.

Please see full Prescribing Information for additional safety information.

See more

IMPORTANT SAFETY INFORMATION FOR PATIENTS

What is REZZAYO® (rezafungin for injection)?

REZZAYO® is an antifungal medication that treats invasive candidiasis, which is an infection of the bloodstream or internal organs caused by a yeast (a type of fungus) called Candida. It is given once-weekly through the vein (intravenous or IV).

REZZAYO® is approved for use in patients 18 years of age and over who have limited or no alternative options for the treatment of their infection. FDA approval of REZZAYO® was based on limited clinical safety and efficacy data. REZZAYO® was not studied in patients with Candida infections in the heart, bone, or brain.